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In this issue of Cancer Cell, Tiberi and colleagues describe a tumor-suppressor role for BCL6. In the
cerebellum, BCL6 is required for the transition from proliferative precursor cell to amore differentiated imma-
ture neuron through repressing the expression of Hedgehog effectors, thus controlling a pathway that is
aberrantly activated in medulloblastoma.Medulloblastoma is the most common
childhood brain tumor. Although the cur-
rent standard of care has led to increased
survival, side effects are significant and
can impact patients’ long term quality of
life. In the past 10 years, a wealth of
studies using genomic and transcriptomic
approaches have allowed division of this
tumor type into multiple clinically relevant
subgroups that may correspond to
distinct cells of origin (Cho et al., 2011;
Gibson et al., 2010; Kool et al., 2008).
Although recent next generation se-
quencing-based analyses revealed that
many of these tumors harbor mutations
affecting epigenetic modifiers (Batora
et al., 2014), the specific mechanisms by
which epigenetic modifications might in-
fluence tumor development are still being
elucidated. In particular, although the
corepressor protein BCOR, a component
of the noncanonical polycomb repressor
complex 1, is frequently mutated in the
Sonic hedgehog (SHH) subgroup of me-
dulloblastoma (multiple studies reviewed
in Batora et al., 2014; Kool et al., 2014),
how these two features might be mecha-
nistically connected was unclear.
In this issue of Cancer Cell, Tiberi et al.
(2014) identify a specific link between the
BCOR corepressor and regulation of the
SHH-driven transcriptional activators
Gli1 and Gli2. The authors further reveal
a prodifferentiative, BCOR-dependent
role for BCL6 in cerebellar neurogenesis
and tumor suppression. Coupled with
other recent studies that have identified
epigenetic regulation as a critical aspect
of the competence of cells to upregulate
Gli1 and other Hedgehog pathway targetgenes (Shi et al., 2014), these data high-
light the importance of chromatin modifi-
cation in enabling a cell to respond to
SHH during normal cerebellar develop-
ment and in activating this pathway during
medulloblastoma development.
The SHH subtype of medulloblastoma
likely originates from cerebellar granule
neuron precursors (GNPs). During post-
natal development of the cerebellum,
GNPs undergo a rapid expansion phase
in a transient surface germinal layer called
the outer external granular layer (EGL).
After exiting the cell cycle, GNPs initiate
radial migration inward from the inner
EGL to the internal granule layer (IGL),
where they complete neuronal differentia-
tion. Dysregulated Hedgehog signaling in
GNPs antagonizes this stereotypic devel-
opmental program, resulting in disrupted
differentiation and persistence of GNPs
in the outer EGL, where cerebellar neo-
plasms are thought to initiate (Figure 1).
The data reported in this issue (Tiberi
et al., 2014) indicate that BCL6, a BTB/
POZ/zinc finger transcriptional repressor,
acts as an intrinsic differentiation factor in
GNPs. BCL6 expression corresponds to
the transition from proliferating GNPs to
immature granule cells in the EGL, be-
cause an absence of BCL6 results in pro-
longed cell cycle progression. However,
mice lacking BCL6 do not exhibit cere-
bellar hyperplasias or tumor development.
Instead, GNPs undergo extensive cell
death, leading to a moderate reduction of
cerebellar size. The cell death is likely
mediated through a p53-dependent
mechanism, because Bcl6; Trp53 double
mutants not only rescue this defect butCancer Cell 26,also develop cerebellar lesions resembling
medulloblastoma. Consistent with its role
as a tumor suppressor, BCL6 overexpres-
sion in a SmoM2-driven medulloblastoma
model is sufficient to substantially delay
tumor growth and extend survival time.
Intriguingly, these effects occur even after
transient overexpression of human BCL6
in an established tumor, raising the ques-
tion of whether overexpression decreases
the pool of available tumor cells through
proliferation block, a burst of differentia-
tion, or through a more complex heritable
epigenetic modification to the affected
cells. Indeed, in the lymphoid system,
transient activity of BCL6 has also been
postulated to have long-term effects on
the epigenetic state of differentiating cells
(Green et al., 2014), and it will be inter-
esting to determine if a similar mechanism
may be at work here.
BCL6 was initially identified as a potent
oncogenic protein in the lymphoid line-
age, where it acts as a transcriptional
repressor by recruiting class I and II his-
tone deacetylase (HDAC) through a core-
pressor complex including BCOR, SMRT,
and NCOR (Huynh et al., 2000). More
recently, BCL6 has been shown to pro-
mote cortical neuronal differentiation
through recruitment of NAD+-dependent
SIRT1 deacetylase to the Hes5 promoter,
thereby epigenetically silencing Notch
signaling (Tiberi et al., 2012). This study
now shows that the BCL6-SIRT1 module
also promotes differentiation of GNPs. In
both normal development of the cere-
bellum and tumor models driven by SHH
pathway-activating mutations, the BCL6-
SIRT1-BCOR complex directly repressesDecember 8, 2014 ª2014 Elsevier Inc. 773
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Figure 1. BCL6 Represses Gli1/2 Transcription during Neuronal Precursor Differentiation
In the developing cerebellum (CB, at left), the external granular layer (EGL) contains dividing granule
neuron precursors (GNPs), which are thought to be a cell of origin for SHH subtype medulloblastoma.
Mitogenic SHH ligand is provided to these precursors by Purkinje cells in the Purkinje cell layer (PCL).
As these precursors complete neurogenesis, they exit the cell cycle and migrate radially through the mo-
lecular layer (ML) to the granule cell layer (GCL). In this issue, Tiberi et al. (2014) show that, while Gli1 and
Gli2 (Gli1 is shown as an example) are expressed in GNPs, during completion of neurogenesis, a complex
including BCL6, BCOR, and SIRT1 represses two activating chromatin marks (green circles and stars)
near the Gli1 and Gli2 promoters. Additional recent studies have also implicated a switch from activating
(green squares) to repressive (red hexagons) chromatin modifications near the Gli1 locus. Additional
experiments by Tiberi et al. (2014) further demonstrate that repression of Gli1 and Gli2 mediated through
the BCL6-BCOR-SIRT1 complex is tumor suppressive in a mouse model of SHH medulloblastoma.
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pathway transcription factors Gli1 and
Gli2 by removing activating chromatin
modifications—in this case, acetylation
of H4K16 and H1.4K26 (Figure 1) (Tiberi
et al., 2014). Intriguingly, recent work
from another group indicates that Gli1
expression is additionally regulated by
histone methylations involving polycomb
repressive complex 2 in a promoter region
near one of the identified BCL6 binding
sites (Shi et al., 2014). How these two
different complexes interact to control
Gli1 expression is an important question
that remains to be determined. In addi-
tion, it is unclear if BCL6 also forms a
complex with HDACs in GNPs; if so,
how does it regulate expression of Gli1
and Gli2? Similarly, what additional mem-
bers of the BCL6-BCOR complex are
active in GNPs when compared to other
maturing cells (both in the CNS and else-
where) where BCL6 is required, and how
is target gene specificity achieved?774 Cancer Cell 26, December 8, 2014 ª201Several small molecules targeting epi-
genetic modifications in medulloblastoma
are already in the initial phase of clinical
trials (Batora et al., 2014). The findings
from this study suggest that the BCL6-
SIRT1-BCOR complex could serve as a
potential therapeutic target for SHH sub-
group medulloblastoma. Notably, small
molecule activators for SIRT1 already
exist; however, in contrast to BCL6 over-
expression, SIRT1 activation showed no
effect on GNP differentiation (Tiberi
et al., 2014). Therefore, specific members
of this complex must be targeted to opti-
mally inhibit GNP-derived tumor growth.
Given that BCL6 is oncogenic in B cell
lymphomagenesis, identifying possible
treatment modalities will require testing
of the systemic effects of agents that
target this complex. Although mutational
data suggest that this complex may be
of primary importance in the SHH subtype
of medulloblastoma, an analysis of exist-
ing transcriptional data indicates that the4 Elsevier Inc.BCL6 gene is downregulated in all other
subtypes as well (multiple studies re-
viewed in Batora et al., 2014; Kool et al.,
2008). It would be interesting to determine
if BCL6 overexpression also inhibits the
growth of medulloblastoma models rep-
resenting non-SHH subgroups. This study
provides an important clue to understand-
ing the chain of events that underlie the
genesis of this childhood tumor and
adds to the mounting evidence indicating
the importance of proper epigenetic regu-
lation in neural development.REFERENCES
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